Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats

British Journal of Pharmacology

Volumn 133, Issue 1, 2001, Pages 179-185

  Coudoré Civiale, Marie Ange ^a   Méen, Murielle ^a   Fournié Zaluski, Marie Claude ^b   Boucher, Michel ^a   Roques, Bernard P ^b   Eschalier, Alain ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

Author keywords

Antinociception; CCK B receptor antagonist; Diabetic rats; Inhibition of enkephalin catabolism; Neuropathy; Opioid receptors; RB 101

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DELTA OPIATE RECEPTOR; ENKEPHALIN; MU OPIATE RECEPTOR; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; NALOXONE; NALTRINDOLE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HYPERALGESIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VOCALIZATION;

EID: 0034982879     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704059     Document Type: Article

References (31)

1. Effects of opioids in a rat model of peripheral mononenropathy
2. Cholecystokimn B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat
3. Spinal effect of the CCK-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats
4. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics
5. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?
6. Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain
7. The dual peptidase inhibitor RB 101 induces a long lasting increase in the extracellular level of Met-enkephalin-like material in the nucleus accumbens of freely moving rats
8. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia
9. Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes
10. Antinociceptive effects of RB 101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist as revealed by noxiously evoked spinal c-Fos expression in rats
11. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity
12. Antinociceptive effect of systemic kelatorphan, in mononeuropathic rats, involves different opioid receptor types
13. Association of the peptidase inhibitor RB 101 and a CCK-B antagonistic strongly enhances antinociceptive responses
14. A method to perform direct transcutaneous intrathecal injections in rats
15. Modulation of opioid antinociception by CCK at the supraspinal level: Evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain
16. Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 101
17. International union of Pharmacology XXI. Structure, distribution and functions of cholecystokinin receptors
18. Naltrindole, an opioid δ antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat
19. Antinociceptive properties of PC 12, a systemically active mixed inhibitor of enkephalin degrading enzymes in normal and arthritic rats
20. 5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adults rats: Effects of dorsal rhizotomy and neonatal capsaicin
21. Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor
22. A method for measurement of analgesic activity on inflamed tissue
23. Neutral endopeptidase 24-11: Structure, inhibition and experimental and clinical pharmacology
24. 3H]diprenorphine binding
25. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation
26. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins
27. Purification, molecular cloning and functional expression of the cholecystokinin receptor from rat pancreas
28. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level
29. The CCK-B antagonist CI-988 enhances the effect of the reflex-depressive effects of morphine in axotomized rats
30. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCK-B receptor antagonist L-365,260 in the rat spinal cord
31. Ethical guidelines for investigations of experimental pain in conscious animals